skip to content

Market News

GlaxoSmithKline upgraded by Berenberg

26 May 2017 14:11

Berenberg has upgraded its recommendation on GlaxoSmithKline (LON:GSK) believing long-term value is emerging and that risks are now skewed to the upside at a group level, despite its HIV business, ViiV, facing competition from Gilead.

The bank also increased its price target to £18.85 (from £18.50).

Berenberg said: "Beyond this near-term risk, we think the market underappreciates the strength and breadth of GSK's diversified business.

"Our base-case SOTP valuation suggests a fair value at £18.54, 14% upside from the closing price."

At 2:11pm: (LON:GSK) GlaxoSmithKline PLC share price was +26.75p at 1644.75p

Story provided by StockMarketWire.com

Related Company: GSK

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.